AUTHORS
Michael D. Bern, MD, PhD, Michael J. Slade, MD, MSCI2, Ravi Vij, MD, MBA3, Keith Stockerl-Goldstein, MD4, Mark Schroeder, MD, MSCI5, Zachary D. Crees, MD6, Maggie Nash7, Hannah Quon8, Grace Hartwig9, Feng Gao, MD, PhD, MPH, MS10, Erik Dubberke, MD11, Chris Farnsworth, PhD12, Brandon Christen13, Michel Morre14, Frederique Berbille15, Michael P. Rettig, PhD16, Richard Hotchkiss, MD17, John F. DiPersio, MD18, Dilan Anil Patel, MD19
AFFILIATIONS
1 Washington University In Saint Louis, Saint Louis, Missouri, United States
2 Washington University In Saint Louis, Saint Louis, Missouri, United States
3 Washington University In Saint Louis, Saint Louis, Missouri, United States
4 Washington University In Saint Louis, Saint Louis, Missouri, United States
5 Washington University In Saint Louis, Saint Louis, Missouri, United States
6 Washington University In Saint Louis, Saint Louis, Missouri, United States
7 Washington University In Saint Louis, Saint Louis, Missouri, United States
8 Washington University In Saint Louis, Saint Louis, Missouri, United States
9 Washington University In Saint Louis, Saint Louis, Missouri, United States
10 Washington University In Saint Louis, Saint Louis, Missouri, United States
11 Washington University In Saint Louis, Saint Louis, Missouri, United States
12 Washington University In Saint Louis, Saint Louis, Missouri, United States
13 Washington University In Saint Louis, Saint Louis, Missouri, United States
14 RevImmune, Paris, France
15 RevImmune, Paris, France
16 Washington University In Saint Louis, Saint Louis, Missouri, United States
17 Washington University In Saint Louis, Saint Louis, Missouri, United States
18 Washington University In Saint Louis, Saint Louis, Missouri, United States
19 Washington University In Saint Louis, Saint Louis, Missouri, United States
ABSTRACT
Introduction: Front-line therapy for multiple myeloma (MM) involves 4-drug induction therapy followed by melphalan autologous hematopoietic cell transplant (AHCT). Melphalan AHCT causes profound lymphopenia, with immune reconstitution taking months to years for some T cell subsets. Early lymphocyte recovery after AHCT has been associated with improved overall survival in MM (Kim et al. Bone Marrow Transplant. 2006). We hypothesized that short-acting recombinant human interleukin-7 (CYT107) administration following consolidative AHCT would be safe, well-tolerated, and enhance lymphocyte reconstitution, which may lead to reduced infectious complications and improved tumor clearance.
Methods: This prospective, single institution, open-label, phase 1 pilot study (NCT06523699) included n=30 patients with MM undergoing consolidation AHCT after achieving a partial response (PR) or better with induction therapy by International Myeloma Working Group (IMWG). Patients were randomized 2:1 to receive either CYT107 (10 ug/kg twice weekly for the first week followed by 20 ug/kg weekly for 3 weeks) or observation after AHCT. The primary endpoint was safety and toxicity. Secondary endpoints included myeloma response by IMWG criteria, measurable residual disease (MRD) negativity by clonoSEQ, incidence of infections, time to engraftment, and reconstitution of immune subsets based on 22-parameter spectral flow cytometry.
Results: At the time of data cut-off, 30 patients have been enrolled. 27/29 patients have received AHCT (1 patient withdrew prior to AHCT), with median post-transplant follow-up of 239 days. Median age was 62 years (range, 44-75 years). 18 (62%) patients were male with 25/29 patients (86%) self-reported as White, 3/29 (10%) Black, and 1/29 (3.4%) Native American/Alaskan. 10 patients were randomized to observation and 19 to CYT107, of which 18 have received at least 1 dose of CYT107. Patients who have completed all planned CYT107 treatments received a median of 5 doses within 1 month following AHCT (68.8% of patients received all 5 doses). The most common treatment-related adverse events attributed to CYT107 were injection site reactions (33.3%) and rash (22.2%). Grade ³3 treatment-related adverse events attributed to CYT107 occurred in 3 patients (rash, hyperbilirubinemia, bone pain). Grade ³3 infections occurred in 4 patients (22.2%) in the CYT107 group and 1 patient (11.1%) in the observation group. Median time to ANC engraftment was 13 and 12 days in the CYT107 and observation arms, respectively. ALC recovery (>1000/ul) at day 30 occurred in 87.5% of patients in the CYT107 group and 55.6% of patients in the observation group. Day 100 response evaluations have been completed in 22 patients (CYT107: 14, observation: 8). The percentage of patients with a complete remission (CR) or better at day 100 was 42.9% in the CYT107 group and 25% in the observation group. MRD-negativity (10-5 threshold) at day 100 was observed in 7/11 MRD-evaluable patients (63.6%) in the CYT107 group and 2/5 patients (40%) in the observation group. All patients are alive at last follow-up.
Flow cytometry has been performed on 12 patients treated with CYT107 and 7 patients on observation. CYT107 treatment was associated with T-cell expansion, with total CD4+ and CD8+ counts increasing 3.2-fold and 2.4-fold, respectively on day 30. Subset analyses demonstrated robust expansion of stem cell memory (CD4 6.9x, CD8 19x), central memory (CD4 3.3x, CD8 9.2x), effector memory (CD4 3.5x, CD8 2x), and TEMRA cells (CD4 3.4x, CD8 2.4x). The magnitude of T-cell expansion positively correlated with baseline CD127 (IL7R) expression, which was highest in stem cell memory and central memory subsets and declined sequentially through naïve, effector populations. CYT107 induced an expected temporary CD127 downregulation without altering markers of T-cell activation or exhaustion.
Conclusion: CYT107 was well-tolerated following AHCT in MM patients. Preliminary results show that patients treated with CYT107 exhibited rapid ALC recovery and pan-T cell reconstitution, including stem cell memory CD4 and CD8 T cells. Follow-up is ongoing to evaluate effects on infectious complications and myeloma response. Future studies are warranted to evaluate CYT107 in combination with T cell-based immunotherapies following AHCT.
DISCLOSURES
Michael D. Bern, MD, PhD: No relevant conflicts of interest to declare.